Phase II Trial of Bortezomib, Low Dose Dexamethasone, and Doxorubicin With Acetyl-L-Carnitine for Neuroprotection in Patients With Previously Treated Multiple Myeloma
The primary objective of this study is to assess overall response rate to the treatment.
Secondary objectives include: evaluating and describing the incidence of
chemotherapy-induced peripheral neuropathy using the FACT/GOG-Ntx assessment tool;
evaluating the utility of adding ALCAR to the chemotherapy to reduce the incidence of
peripheral neuropathy; and evaluating the utility of the Grooved Pegboard Completion Time as
a longitudinal measure of peripheral neuropathy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
measurable serum or urine monoclonal protein
Natalie S Callander, MD
United States: Institutional Review Board
|Regional Cancer Center||Eau Claire, Wisconsin 54701|
|University of Wisconsin Cancer Center||Madison, Wisconsin 53792|
|Gundersen Lutheran||La Crosse, Wisconsin 54601|
|Mercy Health Systems||Janesville, Wisconsin|
|Aspirus Wausau Hospital, Aspirus Regional Cancer Center||Wausau, Wisconsin|